For instance, the FOSL1 transcription factor had been demonstrated to be a major effector of the RAS-ERK1/2 pathway and could increase the metastatic capability of lung cancer by activating epithelial–mesenchymal transition [41]. This evidence concerns the gene MAPK3 and lung cancer.